Summary:
In patients with type 2 diabetes mellitus (T2DM), Ebenatide treatment significantly improved glycemic control (HbA1c), time in range (TIR), triglyceride-glucose index (TyG), weight, and waist-to-height ratio (WHtR) compared to baseline measures, though it was associated with minimal side effects such as mild gastrointestinal symptoms.
| PICO | Description |
|---|---|
| Population | Adults with type 2 diabetes mellitus (T2DM). |
| Intervention | Ebenatide treatment for 24 weeks, sustained for at least 52 weeks, targeting glycemic and metabolic improvement. |
| Comparison | Baseline glycemic and metabolic measures prior to Ebenatide treatment. |
| Outcome | Ebenatide significantly reduced HbA1c and improved glycemic metrics (TIR, TyG). It also lowered body weight and reduced WHtR over 24 weeks, with sustained benefits for at least 52 weeks. Mild gastrointestinal effects were observed as minimal side effects. |
Source: Cheng-Lan Xu, et al. “Effect of Ebenatide on glycemic metabolism and body fat in patients with type 2 diabetes mellitus.” Read article here. Read article here.
